Read by QxMD icon Read

experience of implementing HPV vaccination

Karin Hardt, Paolo Bonanni, Susan King, Jose Ignacio Santos, Mostafa El-Hodhod, Gregory D Zimet, Scott Preiss
Successful immunisation programmes generally result from high vaccine effectiveness and adequate uptake of vaccines. In the development of new vaccination strategies, the structure and strength of the local healthcare system is a key consideration. In high income countries, existing infrastructures are usually used, while in less developed countries, the capacity for introducing new vaccines may need to be strengthened, particularly for vaccines administered beyond early childhood, such as the measles or human papillomavirus (HPV) vaccine...
December 20, 2016: Vaccine
Joël Ladner, Marie-Hélène Besson, Etienne Audureau, Mariana Rodrigues, Joseph Saba
BACKGROUND: Cervical cancer is the greatest cause of age-weighted years of life lost in the developing world. Human papillomavirus (HPV) infection is associated with a high proportion of cervical cancers, and HPV vaccination may help to reduce the incidence of cancer. The aim of the study was to identify barriers, obstacles, and strategies and to analyze key concerns and lessons learned with respect to the implementation of HPV vaccination program in low- and middle-income countries. METHODS: The Gardasil Access Program (GAP) is a donation program established to enable organizations and institutions in eligible low-resource countries to gain operational experience designing and implementing HPV vaccination programs...
October 13, 2016: BMC Health Services Research
Obinna I Ekwunife, James F O'Mahony, Andreas Gerber Grote, Christoph Mosch, Tatjana Paeck, Stefan K Lhachimi
BACKGROUND: Low- and middle-income countries (LMICs) face a number of challenges in implementing cervical cancer prevention programmes that do not apply in high-income countries. OBJECTIVE: This review assessed how context-specific challenges of implementing cervical cancer prevention strategies in LMICs were accounted for in existing cost-effectiveness analysis (CEA) models of human papillomavirus (HPV) vaccination. METHODS: The databases of MEDLINE, EMBASE, NHS Economic Evaluation Database, EconLit, Web of Science, and the Center for the Evaluation of Value and Risk in Health (CEA) Registry were searched for studies published from 2006 to 2015...
January 2017: PharmacoEconomics
Alfredo Aguilar, Joseph A Pinto, Jhajaira Araujo, Williams Fajardo, Leny Bravo, Luis Pinillos, Carlos Vallejos
Cervical cancer is the leading malignant neoplasm in Peruvian women. This malignancy is a public health problem and several efforts were previously performed to develop cancer control plans. Geographical, cultural, structural, infrastructural and procedural barriers can limit the implementation of such strategies. Several previous studies have characterized human papilloma virus (HPV) epidemiology, where prevalence of high-risk HPV in adult females is ~12% and the prevalence in cervical cancer is 90-95%. The predominant barriers for the control of cervical cancer are lack of specialists in remote villages, education/cultural issues, loss of patients in follow-up, lack of access to HPV testing and lack of compliance for HPV vaccination...
August 2016: Molecular and Clinical Oncology
H Patel, K Austin-Smith, S M Sherman, D Tincello, E L Moss
BACKGROUND: The incorporation of Human papillomavirus (HPV) testing into the English cervical screening programme has been met with fear and anxiety. Healthcare professionals need to be adequately informed about HPV to help alleviate patient concerns.The aim of this study was to evaluate the HPV training provided to practice nurses (PNs) and determine their level of HPV knowledge. METHOD: A web-based survey was distributed to 147 General Practice surgeries in the Leicester, Leicestershire and Rutland regions, between May and July 2015...
July 13, 2016: Journal of Public Health
N Howard, S Mounier-Jack, K E Gallagher, S Kabakama, U K Griffiths, M Feletto, D S LaMontagne, H E D Burchett, D Watson-Jones
Demonstration projects or pilots of new public health interventions aim to build learning and capacity to inform country-wide implementation. Authors examined the value of HPV vaccination demonstration projects and initial national programmes in low-income and lower-middle-income countries, including potential drawbacks and how value for national scale-up might be increased. Data from a systematic review and key informant interviews, analyzed thematically, included 55 demonstration projects and 8 national programmes implemented between 2007-2015 (89 years' experience)...
September 2016: Human Vaccines & Immunotherapeutics
S F La Vincente, D Mielnik, K Jenkins, F Bingwor, L Volavola, H Marshall, P Druavesi, F M Russell, K Lokuge, E K Mulholland
BACKGROUND: In 2008 Fiji implemented a nationwide Human Papillomavirus (HPV) vaccine campaign targeting all girls aged 9-12 years through the existing school-based immunisation program. Parents of vaccine-eligible girls were asked to provide written consent for vaccination. The purpose of this study was to describe parents' knowledge, experiences and satisfaction with the campaign, the extent to which information needs for vaccine decision-making were met, and what factors were associated with vaccine consent...
2015: BMC Public Health
Riccardo A Audisio, Giancarlo Icardi, Andrea M Isidori, Carlo A Liverani, Alberto Lombardi, Luciano Mariani, Francesco Saverio Mennini, David A Mitchell, Andrea Peracino, Sergio Pecorelli, Giovanni Rezza, Carlo Signorelli, Giovanni Vitali Rosati, Gian Vincenzo Zuccotti
BACKGROUND: The story of Human Papillomavirus vaccination demands reflection not only for its public health impact on the prophylactic management of HPV disease, but also for its relevant economic and social outcomes. Greater than ever data confirm the efficacy and support the urge for effective vaccination plans for both genders before sexual debut. METHODS: A review of previous experience in gender-restricted vaccination programs has demonstrated a lower effectiveness...
January 2016: Critical Reviews in Oncology/hematology
Celina M Hanson, Linda Eckert, Paul Bloem, Tania Cernuschi
Developing countries disproportionately suffer from the burden of cervical cancer yet lack the resources to establish systematic screening programs that have resulted in significant reductions in morbidity and mortality in developed countries. Human Papillomavirus (HPV) vaccination provides an opportunity for primary prevention of cervical cancer in low-resource settings through vaccine provision by Gavi The Vaccine Alliance. In addition to the traditional national introduction, countries can apply for a demonstration program to help them make informed decisions for subsequent national introduction...
May 20, 2015: Vaccines
Hanna Seitz, Lis Ribeiro-Müller, Elena Canali, Angelo Bolchi, Massimo Tommasino, Simone Ottonello, Martin Müller
Current prophylactic virus-like particle (VLP) human papillomavirus (HPV) vaccines are based on the L1 major capsid protein and provide robust but virus type-restricted protection. Moreover, VLP vaccines have a high production cost, require cold-chain storage, and are thus not readily implementable in developing countries, which endure 85% of the cervical cancer-related death burden worldwide. In contrast with L1, immunization with minor capsid protein L2 elicits broad cross-neutralization, and we previously showed that insertion of a peptide spanning amino acids 20-38 of L2 into bacterial thioredoxin (Trx) greatly enhances its immunogenicity...
October 2015: Cancer Prevention Research
Dafina Petrova, Carol Gray Brunton, Moritz Jaeger, Anita Lenneis, Rocio Munoz, Rocio Garcia-Retamero, Irina Todorova
The Human Papilloma Virus (HPV) is the most common sexually transmitted infection (STI) and can cause cervical cancer. Two vaccines are available to protect against the most common strands of the virus. Vaccination programs differ across Europe but most neglect young adults, who are the group with the highest risk of contracting STIs. Our aim was to explore the views of young women from four European countries—Scotland, Spain, Serbia, and Bulgaria - about the HPV vaccine communication strategy. These countries are characterized by different cervical cancer prevalence and vaccine implementation policies...
2015: Current HIV Research
Deborah Watson-Jones, Nelly Mugo, Shelley Lees, Muthoni Mathai, Sophie Vusha, Gathari Ndirangu, David A Ross
BACKGROUND: Sub-Saharan Africa bears the greatest burden of cervical cancer. Human papillomavirus (HPV) vaccination programmes to prevent the disease will need to reach vulnerable girls who may not be able access health and screening services in the future. We conducted formative research on facilitators and barriers to HPV vaccination and potential acceptability of a future HPV vaccination programme amongst girls living in hard-to-reach populations in Kenya. METHODS: Stakeholder interviews with Ministry of Health staff explored barriers to and support for the uptake of HPV vaccination...
2015: PloS One
Pierre Van Damme, Sven Eric Olsson, Stanley Block, Xavier Castellsague, Glenda E Gray, Teobaldo Herrera, Li-Min Huang, Dong Soo Kim, Punnee Pitisuttithum, Joshua Chen, Susan Christiano, Roger Maansson, Erin Moeller, Xiao Sun, Scott Vuocolo, Alain Luxembourg
OBJECTIVES: Prophylactic vaccination of youngwomen aged 16 to 26 years with the 9-valent (6/11/16/18/31/33/45/52/58) human papillomavirus (HPV) virus-like particle (9vHPV) vaccine prevents infection and disease. We conducted a noninferiority immunogenicity study to bridge the findings in young women to girls and boys aged 9 to 15 years. METHODS: Subjects (N = 3066) received a 3-dose regimen of 9vHPV vaccine administered at day 1, month 2, and month 6. Anti-HPV serologic assays were performed at day 1 and month 7...
July 2015: Pediatrics
Alain Luxembourg, Oliver Bautista, Erin Moeller, Michael Ritter, Joshua Chen
BACKGROUND: The 9-valent human papillomavirus (HPV) (9vHPV) vaccine targets the four HPV types (6/11/16/18) covered by the licensed quadrivalent HPV (qHPV) vaccine and five additional types (31/33/45/52/58). A large outcome trial of 9vHPV vaccine was conducted. METHODS: An active control (qHPV vaccine) was used because a placebo is not ethically acceptable. Since qHPV vaccine is (and 9vHPV vaccine was anticipated to be) highly efficacious against HPV 6/11/16/18, low incidence of HPV 6/11/16/18-associated disease was expected...
May 2015: Contemporary Clinical Trials
Lp Wong, Ic Sam
Certain human papillomavirus (HPV) types are strongly associated with cervical cancer. Recently-described effective vaccines against these HPV types represent a great medical breakthrough in preventing cervical cancer. In Malaysia, the vaccine has just received regulatory approval. We are likely to face similar barriers to implementing HPV vaccination as reported by countries where vaccination has been introduced. Most women have poor understanding of HPV and its link to cervical cancer. Physicians who will be recommending HPV vaccines may not have extensive knowledge or experience with HPV-related disease...
2007: Malaysian Family Physician
Y H Joshua Chen, Richard Gesser, Alain Luxembourg
BACKGROUND: The licensed four-valent prophylactic human papillomavirus vaccine is highly efficacious in preventing cervical, vulvar, vaginal, and anal cancers and related precancers caused by human papillomavirus types 6, 11, 16, and 18. These four types account for approximately 70% of cervical cancers. A nine-valent human papillomavirus vaccine, including the four original types (6, 11, 16, and 18) plus the next five most prevalent types in cervical cancer (31, 33, 45, 52, and 58) could provide approximately 90% overall cervical cancer coverage...
February 2015: Clinical Trials: Journal of the Society for Clinical Trials
Joël Ladner, Marie-Hélène Besson, Mariana Rodrigues, Etienne Audureau, Joseph Saba
BACKGROUND: Cervical cancer is the third most common cancer in women worldwide, with high incidence in lowest income countries. Vaccination against Human Papilloma Virus (HPV) may help to reduce the incidence of cervical cancer. The aim of the study was to analyze HPV vaccination programs performance implemented in low and middle-income countries. METHODS: The Gardasil Access Program provides HPV vaccine at no cost to help national institutions gain experience implementing HPV vaccination...
2014: BMC Public Health
Maria Grandahl, Tanja Tydén, Andreas Rosenblad, Marie Oscarsson, Tryggve Nevéus, Christina Stenhammar
BACKGROUND: Sweden introduced a school-based human papillomavirus (HPV) vaccination programme in 2012, and school nurses are responsible for managing the vaccinations. The aim of the present study was to investigate the attitudes and experiences of school nurses regarding the school-based HPV vaccination programme 1 year after its implementation. METHODS: Data were collected using a web-based questionnaire in the spring of 2013, and 83.1% (851/1024) of nurses responded...
2014: BMC Public Health
Maria-Genalin Angelo, Julia Zima, Fernanda Tavares Da Silva, Laurence Baril, Felix Arellano
PURPOSE: To summarise post-licensure safety surveillance over more than 4 years of routine use of the human papillomavirus-16/18-AS04-adjuvanted vaccine (HPV-16/18 vaccine: Cervarix®, GlaxoSmithKline, Belgium). METHODS: We describe global post-licensure passive surveillance data based on routine pharmacovigilance from 18 May 2007 until 17 November 2011 and enhanced surveillance implemented during the 2-year national immunisation programme in the UK (school years 2008-2010)...
May 2014: Pharmacoepidemiology and Drug Safety
Suzanne M Garland
OBJECTIVE: The goal of this study was to review the current human papillomavirus (HPV) vaccine program and its outcomes to date in Australia. METHODS: This was a review of the published data relating to the introduction and subsequent measurable outcomes of the quadrivalent vaccine, which became part of the Australian national HPV immunization program in 2007. Australia commenced an ongoing, schoolbased, government-funded, HPV vaccination program using the quadrivalent vaccine from April 2007 for adolescent female subjects aged 12 to 13 years, together with a catch-up program for female subjects 13 to 26 years of age from July 2007 to December 31, 2009...
January 1, 2014: Clinical Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"